Matthews GV - Search Results

1

Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs.

Cunningham EB, Hajarizadeh B, Amin J, Hellard M, Bruneau J, Feld JJ, Cooper C, Powis J, Litwin AH, Marks P, Dalgard O, Conway B, Moriggia A, Stedman C, Read P, Bruggmann P, Lacombe K, Dunlop A, Applegate TL, Matthews GV, Fraser C, Dore GJ, Grebely J. Cunningham EB, et al. Among authors: matthews gv. Clin Infect Dis. 2021 Apr 26;72(8):1392-1400. doi: 10.1093/cid/ciaa253. Clin Infect Dis. 2021. PMID: 32166305

2

Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1.

Matthews GV, Pillay D, Cane P, Ratcliffe D, Gazzard B, Nelson M. Matthews GV, et al. Clin Infect Dis. 2001 Dec 15;33(12):2049-54. doi: 10.1086/322655. Epub 2001 Nov 5. Clin Infect Dis. 2001. PMID: 11698987

3

Response to Soriano et al., 'Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis?'.

Matthews G, Dore G. Matthews G, et al. AIDS. 2003 Dec 5;17(18):2675-6. doi: 10.1097/01.aids.0000104338.15729.9a. AIDS. 2003. PMID: 14685063 No abstract available.

4

Treatment for hepatitis C virus infection among current injection drug users in Australia.

Matthews G, Kronborg IJ, Dore GJ. Matthews G, et al. Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S325-9. doi: 10.1086/427448. Clin Infect Dis. 2005. PMID: 15768342 Review.

5

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.

Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL. Matthews GV, et al. AIDS. 2006 Apr 4;20(6):863-70. doi: 10.1097/01.aids.0000218550.85081.59. AIDS. 2006. PMID: 16549970

6

Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'.

Matthews GV, Dore GJ. Matthews GV, et al. AIDS. 2007 Mar 30;21(6):777-8. doi: 10.1097/QAD.0b013e3280b07774. AIDS. 2007. PMID: 17413705 No abstract available.

7

Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.

Matthews GV, Cooper DA, Dore GJ. Matthews GV, et al. Antivir Ther. 2007;12(1):119-22. Antivir Ther. 2007. PMID: 17503756

8

Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.

Revill PA, Littlejohn M, Ayres A, Yuen L, Colledge D, Bartholomeusz A, Sasaduesz J, Lewin SR, Dore GJ, Matthews GV, Thio CL, Locarnini SA. Revill PA, et al. Among authors: matthews gv. AIDS. 2007 Aug 20;21(13):1701-10. doi: 10.1097/QAD.0b013e32826fb305. AIDS. 2007. PMID: 17690567

9

Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al.

Matthews GV, Hellard M, Kaldor J, Lloyd A, Dore GJ. Matthews GV, et al. AIDS. 2007 Oct 1;21(15):2112-3. doi: 10.1097/QAD.0b013e3282ef3873. AIDS. 2007. PMID: 17885306 No abstract available.

10

Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance.

Preiss S, Littlejohn M, Angus P, Thompson A, Desmond P, Lewin SR, Sasadeusz J, Matthews G, Dore GJ, Shaw T, Sozzi V, Yuen L, Lau G, Ayres A, Thio C, Avihingsanon A, Ruxrungtham K, Locarnini S, Revill PA. Preiss S, et al. Hepatology. 2008 Sep;48(3):741-9. doi: 10.1002/hep.22386. Hepatology. 2008. PMID: 18571815 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

259 results

Search Page

Filters